---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-060031"
form_type: "8-K"
ticker: "OLMA"
cik: "0001750284"
company_name: "Olema Pharmaceuticals, Inc."
filed_at: "2024-05-15T23:59:59+00:00"
generated_at: "2026-06-01T23:23:21.398222+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Olema reports interim Phase 1b/2 data: palazestrant + ribociclib shows 85% CBR in ER+/HER2- mBC

## Summary
- Combination well tolerated in 50 patients; no new safety signals and no clinically meaningful drug-drug interaction.
- Clinical benefit rate of 85% (11/13) overall; 83% in ESR1-mutant, 86% in wild-type, 83% in prior CDK4/6i patients.
- Partial responses observed in 5 of 23 evaluable patients (2 confirmed, 3 unconfirmed); 66% remain on treatment.
- Study fully enrolled at 60 patients; data support continued development for first-line ER+/HER2- advanced breast cancer.

## SEC filing metadata
- accession: 0000950170-24-060031
- form_type: 8-K
- ticker: OLMA
- cik: 0001750284
- company_name: Olema Pharmaceuticals, Inc.
- filed_at: 2024-05-15T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1750284/000095017024060031/0000950170-24-060031-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1750284/000095017024060031/olma-20240515.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-060031
- JSON: https://secwatch.observer/filing/0000950170-24-060031.json
- Plain text: https://secwatch.observer/filing/0000950170-24-060031.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.